Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by factor VIII (FVIII) autoantibodies that interfere with FVIII coagulant function, predisposing affected patient to an often severe bleeding diathesis. The management of AHA is primarily directed toward the eradication of ...
We conclude that rhFVIIa is a safe, effective, and fast-acting preparation for the treatment of severe hemorrhage in patients with acquired hemophilia A, and that the simultaneous administration of azathioprine and corticosteroids may suppress production of the inhibitor....
Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Mod Rheumatol 2011; 21:420-2.Nishida S, Kawasaki T, Kashiwagi H et al (2011) Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Mod Rheumatol 21(4):420–422...
Acquired hemophilia A (AH) is an autoimmune disease that leads to potentially severe bleeding. Management relies on rapid and accurate diagnosis, control of bleeding episodes and eradication of the inhibitor by immunosuppression. There is extensive literature about the disease but only few controlled da...
The treatment of acquired hemophilia A has two main goals: (1) to treat and/or prevent bleeding complications and (2) to eradicate the inhibitor. The recommended agents to be used for the treatment or prevention of bleeding in patients with acquired hemophilia A are the bypassing agents. ...
Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII). Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of patients over a period of days to months. IST is associated with frequent adverse events, including infections as a leading ca...
rom a single center Treatment and complications in acquired hemophilia A. Experience from a single centerTreatment and complications in acquired hemophilia A. Experience from a single centerdoi:10.1016/j.medcle.2017.10.008LauraEntrenaUreaDolores
Acquired hemophilia A (AHA) is a bleeding disorder that occurs from aberrant production of autoantibodies that target factor VIII. The underlying cause of AHA is unclear but can present postpartum. Very few cases have reported instances of AHA coexisting with other hematological disorders, such as ...
OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence, is a recombinant DNA derived, antihemophilic factor indicated for the on-demand treatment and control of bleeding episodes in adults with acquired hemophilia A. Limitations of Use: ...
Consensus recommendations for the diagnosis and treatment of acquired hemophilia A p pBackground/p pAcquired hemophilia A (AHA) is a rare bleeding disorder caused by an autoantibody to coagulation factor (F) VIII. It is characterized by s... S Midori,C Maria,CM Kessler,... - 《Bmc Researc...